NCT07140211

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis: a Pragmatic, Multi-center, Open-label Randomized Controlled Study

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 9,200 (estimated)
• Sponsor: Marc Blondon · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.

Conditions

• Venous Thromboembolism (VTE)
• Postpartum

Interventions

Type	Name	Description
DRUG	Low-dose low-molecular-weight heparin	Low-molecular-weight heparin given for 7-10 days after delivery: * enoxaparin 4000-6000IU o.d. * nadroparin 3800-5700IU o.d. * dalteparin 5000-7500IU o.d. * tinzaparin 4500-7000IU o.d.

Timeline

• Start date: 2025-10-15
• Primary completion: 2030-08-01
• Completion: 2030-08-01
• First posted: 2025-08-24
• Last updated: 2026-02-17

Locations

1 site across 1 country: Switzerland